Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Carboplatin

Capecitabine

Letrozole

Albumin-Bound Paclitaxel

Goserelin

Pertuzumab

Androgen Receptor Antagonists

6 cycles of Paclitaxel,Carboplatin, Herceptin and Pertuzumab treatment with a good clinical benefit response depending on HR/HER-2 status.

2 cycles of Paclitaxel,Carboplatin, Herceptin treatment with a good clinical benefit response depending on HR/HER-2 status following surgery

If patients were HR+ and HER2- without PI3K-AKT pathway mutation

If patients were HR+ and HER2- with PI3K-AKT pathway mutation

If patients were HR+ and HER2+ without PI3K-AKT pathway mutation

If patients were HR+ and HER2+ with PI3K-AKT pathway mutation

If patients were HR- and HER2+ without PI3K-AKT pathway mutation

If patients were HR- and HER2+ with PI3K-AKT pathway mutation

If patients were HR- and HER2- with LAR subtype

HR+ and HER2-; No correlated pathway variation

TNBC with Homologous Recombination Repair Defect (HRD)

Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle. Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle,6 cycles.

Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle,6 cycles.

Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.

Drug:

SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off) oral letrozole 2.5 mg daily； Premenopause：Goserelin 3.6mg IM IM Q4W.

Drug:

SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off); Alpelisib 300mg PO QD； Premenopause：Goserelin 3.6mg IM IM Q4W.

Drug:

SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off) oral letrozole 2.5 mg daily； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle； Premenopause：Goserelin 3.6mg IM IM Q4W.

CLH1

Drug:

oral letrozole 2.5 mg daily; Alpelisib 300mg PO QD； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle； Premenopause：Goserelin 3.6mg IM IM Q4W.

CLH2

Drug:

pyrotinib(EGFR-TKI) 400mg qd； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； capecitabine 1000mg/m2 bid(d1-d14)

Drug:

Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Alpelisib 300mg PO QD； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle； Premenopause：Goserelin 3.6mg IM IM Q4W.

Drug:

SHR6390（CDK4/6 inhibitor）125 mg po.qd(three week on one week off) SHR3680（AR inhibitor）240 mg po. qd.

SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off); oral letrozole 2.5 mg daily； Adebrelimab was given intravenously, 600mg each time, once every 2 weeks; Premenopause：Goserelin 3.6mg IM IM Q4W.

Famitinib 20mg orally once daily; Albumin paclitaxel 100mg/ m2, i.v.; Combined carboplatin AUC=2, i.v.; d1, 8, 15,21 days a cycle, a total of 4 cycles.

Fluzoparil 150mg orally twice daily; Famitinib 20mg orally once daily;

Adebrelimab was administered intravenously, 600mg each time, once every 2 weeks; Famitinib 20mg once daily; Albumin paclitaxel 100mg/m2 qw intravenous drip (used for 3 weeks/stopped for 1 week), 28 days per treatment cycle;

Zhimin Shao, MD.PhD.

Zhimin Shao, PhD

This is a Phase Ib/II, prospective , open-label, single center, Bayesian adaptive design, umbrella study evaluating the efficacy and safety of neo-adjuvant therapy in patients with breast cancer.

A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

This is a Phase Ib/II, Prospective , Open-label, Single Center, Bayesian Adaptive Design, Umbrella Study Evaluating the Efficacy and Safety of Neo-adjuvant Therapy in Patients With Breast Cancer.

pCR is defined as the absence of noninvasive tumor residuals in breast and axillary lymph nodes (ypT0/is ypN0) after neoadjuvant therapy.

ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC	NCT04215003	Breast Cancer	A B CL1 CL2 CLH1 CLH2 CH1 CH2 CT1 CL4 CL3 CT2 CT3 CT4	18 Years - 70 Years	Fudan University
A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC	NCT04215003	Breast Cancer	A B CL1 CL2 CLH1 CLH2 CH1 CH2 CT1 CL4 CL3 CT2 CT3 CT4	18 Years - 70 Years	Fudan University

Spots Global Cancer Trial Database for clh1

Every month we try and update this database with for clh1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for clh1

Every month we try and update this database with for clh1 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for clh1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.